Eli Lilly and Company $LLY Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 162.2% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 318,993 shares of the company’s stock after acquiring an additional 197,315 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Eli Lilly and Company were worth $263,303,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. JB Capital LLC raised its stake in shares of Eli Lilly and Company by 10.8% during the 3rd quarter. JB Capital LLC now owns 1,214 shares of the company’s stock valued at $926,000 after buying an additional 118 shares during the last quarter. Mainstream Capital Management LLC grew its stake in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Mainstream Capital Management LLC now owns 2,318 shares of the company’s stock worth $1,769,000 after purchasing an additional 20 shares during the period. Stonebridge Financial Group LLC increased its holdings in shares of Eli Lilly and Company by 2.0% during the 3rd quarter. Stonebridge Financial Group LLC now owns 998 shares of the company’s stock valued at $761,000 after purchasing an additional 20 shares in the last quarter. Shum Financial Group Inc. acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $1,225,000. Finally, Merit Financial Group LLC boosted its stake in shares of Eli Lilly and Company by 6.2% during the 3rd quarter. Merit Financial Group LLC now owns 34,453 shares of the company’s stock worth $26,288,000 after acquiring an additional 2,023 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY stock opened at $1,075.00 on Friday. The business has a 50 day moving average price of $1,008.08 and a 200 day moving average price of $848.52. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.59, a PEG ratio of 1.09 and a beta of 0.37. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the business posted $1.18 EPS. The company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 33.86%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Berenberg Bank raised their price target on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday, December 2nd. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. National Bankshares set a $1,286.00 price objective on shares of Eli Lilly and Company in a report on Monday, December 1st. Leerink Partners reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, December 18th. Finally, Wolfe Research lifted their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,155.36.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.